Clinical trials: Normal Population
Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM)
The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM
This trial is a pivotal, placebo-controlled, double-blind, parallel-group, adaptive trial conducted in subjects with DM and CLI Rutherford Category 5.
- Conditions
- Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03174522
- Testing
- REX-001
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 49 people
- Sponsor
- Ixaka Ltd
Impetigo
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
The purpose of the study is to show non inferiority in terms of safety and efficacy of topical administration BID (Twice daily) of Mupirocin Gel 20 mg/g compared to topical administration of Mupirocin Ointment 20 mg/g TID (three…
- Trial name
- NCT04287777
- Testing
- Mupirocin gel, Mupirocin ointment
- Where
- 20 sites in Spain
- Volunteers
- 467 people
- Sponsor
- Reig Jofre Group
Arthritis, Rheumatoid
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis
- Trial name
- NCT00256919
- Testing
- GW856553
- Where
- 17 sites in Bulgaria, Germany and 3 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Lupus Nephritis
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus…
- Trial name
- NCT00705367
- Testing
- Abatacept
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN)
This is a Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to evaluate the efficacy and safety of N1087 in women with female pattern hair loss (FPHL).
- Trial name
- MINORA-WOMEN (NCT07303322)
- Testing
- N1087
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
External Genital Warts
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%.
- Trial name
- NCT02482428
- Testing
- Investigational Treatment, Aldara
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT04914429
- Testing
- Guselkumab
- Where
- 26 sites in China
- Volunteers
- 327 people
- Sponsor
- Janssen Research & Development, LLC
Actinic Keratoses
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face…
- Trial name
- AK003 (NCT03285477)
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
The study will assess the safety and efficacy of QGE031 in the treatment of moderate to severe atopic dermatitis patients. In addition, QGE031 levels in the blood will be measured and the effect of QGE031 on markers in the blood…
- Trial name
- NCT01552629
- Testing
- QGE031, Cyclosporine A
- Where
- 4 sites in Austria, France and 1 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
- Trial name
- NCT01017146
- Testing
- Tazarotene foam, Vehicle Foam
- Where
- 22 sites in United States, Canada
- Volunteers
- 744 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.
- Trial name
- NCT02073461
- Testing
- CD1579 2.5%, CD1579 5%, Vehicle
- Where
- 6 sites in Japan
- Volunteers
- 236 people
- Sponsor
- Galderma R&D
Moderate Hepatic Impairment, Normal Hepatic Function
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
The purpose of this study is to determine the effect of hepatic impairment on rivipansel PK and safety.
- Trial name
- NCT02871570
- Testing
- Rivipansel
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlycoMimetics Incorporated
Hepatic Impairment
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.
- Trial name
- NCT00432627
- Testing
- Deferasirox
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Normal Healthy Subject Population
Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.
- Trial name
- NCT00808769
- Testing
- Zegerid®, Prilosec OTC®
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Diabetic Foot Ulcer
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.
- Trial name
- FEENICS (NCT00662831)
- Testing
- Fragmin/ Dalteparin Sodium
- Where
- 63 sites in Austria, Belgium and 15 more
- Volunteers
- 276 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.
- Trial name
- SCRIPT (NCT00476996)
- Testing
- Leflunomide, Methotrexate, Ocrelizumab
- Where
- 266 sites in United States, Argentina and 23 more
- Volunteers
- 836 people
- Sponsor
- Genentech, Inc.
Hepatic Impairment
PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
The purpose of this international study was to assess the effect of varying degrees of impaired hepatic function compared to a normal hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of midostaurin.
- Trial name
- NCT01429337
- Testing
- Midostaurin
- Where
- 7 sites in United States, Belgium and 4 more
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Digital Ulcers
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
The DUAL-2 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration.
- Trial name
- DUAL-2 (NCT01474122)
- Testing
- Macitentan 3 mg, Macitentan 10 mg
- Volunteers
- 265 people
- Sponsor
- Actelion
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04921345
- Testing
- Nemolizumab
- Where
- 23 sites in United States, Denmark and 3 more
- Volunteers
- 109 people
- Sponsor
- Galderma R&D
Hepatic Insufficiency
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Assessment of the effect of moderate liver impairment (Child-Pugh classification B) on the pharmacokinetics and pharmacodynamics of dabigatran after oral administration of dabigatran etexilate.
- Trial name
- NCT02170571
- Testing
- Dabigatran etexilate
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.